Zevra Therapeutics (ZVRA) Price & Analysis

Compare

904 Followers

ZVRA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.45 - $11.59

Previous CloseN/A

Volume189.47K

Average Volume (3M)730.16K

Market Cap

$616.24M

Enterprise Value$527.00M

Total Cash (Recent Filing)$37.34M

Total Debt (Recent Filing)$61.84M

Price to Earnings (P/E)―

Beta0.95

Next Earnings

Aug 19, 2025

EPS Estimate

2.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding54,679,640

10 Day Avg. Volume1,136,150

30 Day Avg. Volume730,163

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)12.12

Price to Sales (P/S)0.00

P/FCF Ratio-8.13

Enterprise Value/Market Cap0.86

Enterprise Value/Revenue4.66

Enterprise Value/Gross Profit16.47

Enterprise Value/Ebitda-1.91

Forecast

1Y Price Target

$23.50

Price Target Upside103.46% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Zevra Therapeutics News

See All ZVRA News

See All News >

Bulls Say, Bears Say

Bulls Say

Commercial SuccessZevra Therapeutics has successfully transitioned into a commercial-stage rare disease company with multiple levers for further long-term value creation.

FDA ApprovalFDA approval of Miplyffa for Niemann-Pick disease type C marked the first FDA-approved therapy for NPC.

Financial PerformanceZevra reported net revenue of $20.4M, beating consensus and forecast, with Miplyffa generating $17.1M in net revenue.

Bears Say

Cash Runway UncertaintyZVRA did not specifically provide an updated cash runway, but said it has 'ample resources and financial flexibility to execute on our strategic priorities independent from the capital markets.'

Olpruva RevenueOlpruva's revenue remains modest despite a strategy focused on targeting adult patients with reimbursement challenges.

Patient Conversion InformationZVRA did not provide a specific number to our question on how many patients are on the product and what fraction might be 'paid patients'.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.64% Insiders

10.68% Mutual Funds

33.94% Other Institutional Investors

44.35% Public Companies and Individual Investors

Detailed Ownership Overview >

ZVRA FAQ

What was Zevra Therapeutics’s price range in the past 12 months?

Zevra Therapeutics lowest stock price was $5.45 and its highest was $11.59 in the past 12 months.

What is Zevra Therapeutics’s market cap?

Zevra Therapeutics’s market cap is $616.24M.

When is Zevra Therapeutics’s upcoming earnings report date?

Zevra Therapeutics’s upcoming earnings report date is Aug 19, 2025 which is in 40 days.

How were Zevra Therapeutics’s earnings last quarter?

Zevra Therapeutics released its earnings results on May 13, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.181 by $0.121.

Is Zevra Therapeutics overvalued?

According to Wall Street analysts Zevra Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zevra Therapeutics pay dividends?

Zevra Therapeutics does not currently pay dividends.

What is Zevra Therapeutics’s EPS estimate?

Zevra Therapeutics’s EPS estimate is 2.17.

How many shares outstanding does Zevra Therapeutics have?

Zevra Therapeutics has 54,679,640 shares outstanding.

What happened to Zevra Therapeutics’s price movement after its last earnings report?

Zevra Therapeutics reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.181. Following the earnings report the stock price went up 3.431%.

Which hedge fund is a major shareholder of Zevra Therapeutics?

Currently, no hedge funds are holding shares in ZVRA

Zevra Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-204.78%

Trailing 12-Months

Asset Growth

14.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Zevra Therapeutics

Zevra Therapeutics (ZVRA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare diseases and unmet medical needs. The company operates within the healthcare sector, specifically targeting the pharmaceutical industry. Its core products include a pipeline of drug candidates in various stages of clinical development, aiming to address serious health conditions where existing treatments are inadequate.

ZVRA Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong performance and strategic progress, especially with the successful launch of MIPLYFFA and robust financial positioning. However, challenges remain with OLPRUVA's market penetration and limited initial market access for MIPLYFFA.Read More>

ZVRA Stock 12 Month Forecast

Average Price Target

$23.50

▲(103.46%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","9":"$9","15":"$15","21":"$21","27":"$27"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,9,15,21,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.95,10.26153846153846,11.573076923076922,12.884615384615383,14.196153846153845,15.507692307692306,16.81923076923077,18.130769230769232,19.442307692307693,20.753846153846155,22.065384615384616,23.376923076923077,24.68846153846154,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.95,10.069230769230769,11.188461538461539,12.307692307692307,13.426923076923076,14.546153846153846,15.665384615384614,16.784615384615385,17.903846153846153,19.02307692307692,20.142307692307693,21.26153846153846,22.380769230769232,{"y":23.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.95,9.723076923076922,10.496153846153845,11.269230769230768,12.042307692307691,12.815384615384614,13.588461538461537,14.361538461538462,15.134615384615383,15.907692307692308,16.68076923076923,17.453846153846154,18.22692307692308,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.6,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.65,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.65,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.84,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >